このアイテムのアクセス数: 88

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
17_0775.pdf314.56 kBAdobe PDF見る/開く
タイトル: Cefazolinに関する基礎的ならびに臨床的検討
その他のタイトル: Laboratory and clinical evaluation of Cefazolin
著者: 桐山, 啻夫  KAKEN_name
多嘉良, 稔  KAKEN_name
林田, 重昭  KAKEN_name
酒徳, 治三郎  KAKEN_name
著者名の別形: Kiriyama, Tadao
Takara, Minoru
Hayashida, Shigeaki
Sakatoku, Jisaburo
キーワード: Adult
Aged
Cephalosporins/pharmacology/therapeutic use
Escherichia coli/drug effects
Evaluation Studies as Topic
Female
Humans
Klebsiella/drug effects
Male
Middle Aged
Proteus/drug effects
Pseudomonas aeruginosa/drug effects
Staphylococcus/drug effects
Urinary Tract Infections/drug therapy
発行日: Dec-1971
出版者: 泌尿器科紀要刊行会
誌名: 泌尿器科紀要
巻: 17
号: 12
開始ページ: 775
終了ページ: 780
抄録: The report deals with the laboratory and clinical assessment of Cefazolin (CEZ) on urinary tract infections. The results obtained were summarized as follows. 1) The MIC of CEZ against 164 strains of the bacteria isolated from secondary urinary tract infections were determined by the plate dilution method. The MIC were less than 12.5 meg/ml in 50% of Staphylococcus aureus, 60% of Staphylococcus epidermidis, 25% of Enterococcus, 45.4% of Klebsiella, 88.5% of E. coli, and only 4.8% of Pseudomonas aeruginosa. 2) Serum concentration following an intramuscular administration of 500 mg in two healthy adults reached the peak level of 32.2mcg/ml in average after one hour. Urinary recovery was 87.9% for 24 hours. 3) Of eight patients with the urinary tract infection secondary to urological surgeries, six were treated effectively by parenteral administration of 1.0 to 2.0 gm a day for 5 to 7 days. 4) No significant changes in blood chemistry were noticed in the patients receiving intravenously total of 10 to 18 gm.
URI: http://hdl.handle.net/2433/121325
PubMed ID: 5004290
出現コレクション:Vol.17 No.12

アイテムの詳細レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。